Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 15CNS 2Thoracic 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Recurrence 1Neoplasm Metastasis 1Melanoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 73Nivolumab 27atezolizumab 15Docetaxel 10Cyclophosphamide 10cemiplimab 9Ipilimumab 9Paclitaxel 8Interleukin-2 8Biopsy 7fludarabine 6durvalumab 6avelumab 6Taxes 6Specimen Handling 6epacadostat 5Magnetic Resonance Spectroscopy 5Immune Checkpoint Inhibitors 5Gemcitabine 5Drug Therapy 5Cisplatin 5Carboplatin 5spartalizumab 4Radiotherapy 4Radiosurgery 4Pemetrexed 4Cetuximab 4utomilumab 3trametinib 3poly ICLC 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Opdualag × Head & Neck × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡